LONDON, UK: Ananda Development Plc, a company developing cannabinoid-based medicines for complex, chronic inflammatory pain conditions, has launched its first two products MRX1 and MRX2 on the UK specials market.
The products are oil formulations containing cannabidiol (CBD), a non-psychoactive compound derived from cannabis, and other ingredients.
The products will be available for prescription by specialist doctors at three private pain and medical cannabis clinics in the UK.
MRX1 will also be used in two clinical trials at the University of Edinburgh, funded by £1.55m of grants, to test its effectiveness in treating chemotherapy-induced nerve pain and endometriosis.
Ananda’s CEO, Melissa Sturgess, said: “We are determined to win NHS support for our cannabinoid medicines with our rigorous approach to formulation development, clinical trials and traditional pharmaceutical data collection. We believe that MRX is in the strongest position to do exactly that. With NHS endorsement we can bring these medicines to the millions of people who need them and deliver revenues to Ananda.”
Emriya to help commercialise and regulatory acceptance of Zelira’s medicinal cannabis products